Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Overview of attention for article published in Journal of Clinical Oncology, September 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 4 news outlets
policy: 1 policy source

twitter: 46 X users
reddit: 1 Redditor

Readers on

mendeley: 150 Mendeley

Summary News Policy documents X Reddit

So far, Altmetric has seen 51 X posts from 46 X users, with an upper bound of 190,544 followers.

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study | Journal of Clinical Oncology https://t.co/lvaSghwssa

22 Jan 2021

Reply Repost Favourite

New2Trip: Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4 yr Results & Evaluation of Impact of Genomic Complexity & Gene Mutations From MURANO Phase III Study https://t.co/HCA3eYvuzj

10 Jan 2021

Reply Repost Favourite

@marcellorotta1 @EghtedarAli @MichaelMaris8 @LukeMtjoy

07 Dec 2020

Reply Repost Favourite

RT @pb10_bmt: Relapsed #CLL. >Lower responses with genetically complex disease > VEN-R vs BR (left vs right) shows better survival across a…

07 Dec 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 47 additional X posts.